Nj State Employees Deferred Compensation Plan Viking Therapeutics, Inc. Transaction History
Nj State Employees Deferred Compensation Plan
- $824 Million
- Q3 2024
A detailed history of Nj State Employees Deferred Compensation Plan transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Nj State Employees Deferred Compensation Plan holds 38,000 shares of VKTX stock, worth $1.51 Million. This represents 0.29% of its overall portfolio holdings.
Number of Shares
38,000
Previous 38,000
-0.0%
Holding current value
$1.51 Million
Previous $2.01 Million
19.41%
% of portfolio
0.29%
Previous 0.26%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
65.6MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$404 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$240 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$186 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$84.2 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$74.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.05B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...